A prespecified analysis of the NOAH-AFNET 6 trial investigated the impact of kidney function on cardiovascular outcome in patients with device-detected atrial fibrillation. Today, the findings were ...
Hosted on MSN
Anticoagulation offers no clear benefit in patients with device-detected atrial fibrillation
A Win Ratio analysis confirmed the primary result of the NOAH—AFNET 6 trial and did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with device-detected ...
A combined subgroup analysis of the similar trials NOAH—AFNET 6 and ARTESiA has revealed that patients with device-detected atrial fibrillation and concomitant vascular disease are at higher risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results